OConnell Daniel Joseph Insider Trading Activity

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
3
Insider Sells Sum
$160,728.49

Insider Activity of OConnell Daniel Joseph

According to the SEC Form 4 filings, OConnell Daniel Joseph, being in a position of

  1. Chief Executive Officer at Acumen Pharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 86013 shares for $163,123,
    over all time since 2024-01-19, has bought 0 shares, and sold 161610 shares for $323,852.

Biography of OConnell Daniel Joseph

No biography is available at this moment.

Statistics of Insider Transactions Last Year

Amount of Insider Buys and Sells by Stocks

Buys
$000
Sells
$163,1238100

Comparison of Insiders on Amount of Buys and Sells

2026-01-22SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
2,689
0.0042%
$1.88$5,066+26.13%
2026-01-21SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
9,346
0.0154%
$1.81$16,927+38.67%
2026-01-12SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
5,388
0.0089%
$1.73$9,307+44.77%
2026-01-09SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
12,941
0.0208%
$1.76$22,832+37.57%
2026-01-08SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
8,143
0.0131%
$1.82$14,815+33.6%
2026-01-07SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
37,755
0.0622%
$1.99$74,981+24.62%
2026-01-06SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
5,102
0.0084%
$1.97$10,032+26.53%
2026-01-05SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
4,649
0.0076%
$1.97$9,163+25.25%
2025-01-21SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
12,619
0.0202%
$1.59$20,102-14.72%
2025-01-03SaleAcumen Pharmaceuticals, Inc.
ABOS
Chief Executive Officer
47,778
0.0774%
$1.84$87,873-26.84%
2024-01-19SaleAcumen Pharmaceuticals, Inc.
ABOS
President and CEO
15,200
0.0253%
$3.47$52,753-21.82%
Total: 11
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.